Clinical Trials Browser

Erlotinib Hydrochloride × Head & Neck × 1 year × Clear all

Squamous Cell Carcinoma of Head and Neck, Leiomyosarcoma, Histiocytoma, Malignant Fibrous, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT00954226 2025-09-05

Phase Ib Study of Erlotinib Prior to Surgery in Patients With Head and Neck Cancer

Phase 1 Completed

48 enrolled

Head & Neck

Salivary Gland Neoplasms

NCT06997068 2025-07-14

Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Oral Cavity Cancer in a Rural Midwest United States Population

Phase 2 Recruiting

25 enrolled

Head & Neck

Mouth Neoplasms

NCT00076310 2025-06-26

OSI-774/Cisplatin/Taxotere in Head & Neck Squamous Cell Cancer

Phase 2 Active not recruiting

50 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasms, Squamous Cell

NCT00405405 2025-05-06

Phase I of Biologics and Chemoradiation Therapy for Advanced Head and Neck Cancer

Phase 1 Completed

13 enrolled

DermatologicHead & Neck

Head and Neck Neoplasms, Melanoma, Parotid Neoplasms, Thyroid Neoplasms

NCT00942734 2025-05-01

Trial of RAD001 and Erlotinib With Recurrent Head and Neck Squamous Cell Carcinoma

Phase 2 Completed

49 enrolled 5 charts

Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms

Clinical Trials

POTENTIATE

Phase Ib Study of Erlotinib Prior to Surgery in Patients With Head and Neck Cancer

Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Oral Cavity Cancer in a Rural Midwest United States Population

OSI-774/Cisplatin/Taxotere in Head & Neck Squamous Cell Cancer

Phase I of Biologics and Chemoradiation Therapy for Advanced Head and Neck Cancer

Trial of RAD001 and Erlotinib With Recurrent Head and Neck Squamous Cell Carcinoma